Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYF

06.08.2022 - Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment ...

Related Keywords

United Kingdom , California , United States , San Francisco , Ukraine , American , Reprod Genet , Uneek Mehra , James Rusnak , Linda Giudice , Arjona Ferreira , University Of California , Linkedin , Twitter , Adamson , Pfizer , Sumitomo Pharma Co Ltd , Facebook , Program Steering Committee , Myovant Sciences Forward , Effect On Other Laboratory , American Society For Reproductive Medicine , Myovant Sciences , European Commission , Drug Administration , Women Health , Global Product Development , Exchange Commission , Myovant Sciences Contacts , Youtube , Corporate Communications , Myovant Sciences Inc , Healthcare Products Regulatory Agency , Sumitovant Biopharma Ltd , Senior Vice , Chief Development Officer , Internal Medicine , Distinguished Professor , Boxed Warning , Sensitive Malignancies , Mood Disorders , Including Depression , Transaminase Elevations , Cholestatic Jaundice , Blood Pressure , Menstrual Bleeding Pattern , Reduced Ability , Recognize Pregnancy , Early Pregnancy Loss , Fibroid Prolapse , Lipid Metabolism , P Gp Inhibitors , United Kingdom Medicines , New Drug Application , United States Prescribing Information , Sumitovant Biopharma , Breakthroughs That Change Patient , Private Securities Litigation Reform Act , Myovant Science , United States Securities , Quarterly Report , Annual Report , Looking Information , Factors That May Affect Future , Reproductive Medicine , Human Reproduction , Best Pract Res Clin Obstet , Gynecol Obstet ,